Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation [Yahoo! Finance]
Pulse Biosciences, Inc (PLSE)
Last pulse biosciences, inc earnings: 11/7 03:42 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.pulsebiosciences.com
Company Research
Source: Yahoo! Finance
HAYWARD, Calif., March 09, 2026 BUSINESS WIRE )--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced clinical data on outcomes durability from the nPulse Vybrance Percutaneous Electrode System First-in-Human ablation study of benign thyroid nodules using nsPFA energy. The long-term follow-up from this study demonstrates significant and sustained volume reduction of treated benign thyroid nodules at 15-22 months, with no tissue regrowth and no serious adverse events. These data were presented by Prof. Stefano Spiezia on Friday March 6, 2026 at the North American Society for Interventional Thyroidology 2026 meeting, which took place in Portland, OR. Key study findings include: Durable 15-22 month results with an average of 74% volume reduction of treated benign thyroid nodules with overwhelming patient satisfaction reported Continued volume reduct
Show less
Read more
Impact Snapshot
Event Time:
PLSE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLSE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLSE alerts
High impacting Pulse Biosciences, Inc news events
Weekly update
A roundup of the hottest topics
PLSE
News
- Truffle Capital Unveils the First Edition of the Truffle MedTech 10 [Yahoo! Finance]Yahoo! Finance
- Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data [Yahoo! Finance]Yahoo! Finance
- Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical DataBusiness Wire
- Is Pulse Biosciences' (PLSE) Thyroid Cancer Feasibility Study a Prelude to a Broader Platform Strategy? [Yahoo! Finance]Yahoo! Finance
- A Look At Pulse Biosciences (PLSE) Valuation As Thyroid Cancer Feasibility Study Begins [Yahoo! Finance]Yahoo! Finance
PLSE
Earnings
- 2/19/26 - Beat
PLSE
Sec Filings
- 3/17/26 - Form 8-K
- 3/12/26 - Form 8-K
- 3/9/26 - Form 8-K
- PLSE's page on the SEC website